Juvenile Arthritis

Initial biologic therapy is now the most common treatment for children with systemic juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry, according to data presented at ACR Convergence 2021.

Early, aggressive treatment with a biologic alongside a conventional DMARDs for juvenile idiopathic arthritis achieved clinically inactive disease at 24 months more frequently than other strategies, said a presenter at ACR Convergence 2021.

Black children with lupus are significantly more likely than white children to have an adverse renal outcome at any hospital encounter, despite an overall decrease in said outcomes since 2006, according to data presented at ACR Convergence 2021.

Eye exam reminders at every visit are associated with higher uveitis knowledge among patients with juvenile idiopathic arthritis and their parents, according to data published in Pediatric Rheumatology.

Living under COVID-19 lockdown was associated with a higher rate of joint inflammation in children with juvenile idiopathic arthritis, according to data from an Italian cohort published in Arthritis Care & Research.

Three strategies aimed at starting patients with polyarticular juvenile idiopathic arthritis on different combinations of DMARDs and biologics resulted in similar rates of clinically inactive disease without glucocorticoids at 12 months, according to data.

Parents reported that two-thirds of children with juvenile idiopathic arthritis demonstrate drug side effects that impact their quality of life within 1 year of diagnosis, according to data published in Arthritis Care & Research.

During the early months of the COVID-19 pandemic, increased all-cause mortality in patients with rheumatoid arthritis and other inflammatory joint diseases largely mirrored that of the general population, according to data.

Subcutaneous tocilizumab provides similar exposure and risk-benefit profiles as intravenous tocilizumab in patients with systemic juvenile idiopathic arthritis, according to findings published in Rheumatology.

A subset of patients with systemic juvenile idiopathic arthritis with elevated interleukin-18 markers could face “increased risk” for macrophage activation syndrome, according to a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.